Posted by Michael Wonder on 24 Feb 2024
Bristol Myers Squibb receives positive CHMP opinion for Reblozyl (luspatercept) for treatment of adults with transfusion-dependent anaemia due to low- to intermediate-risk myelodysplastic syndromes
23 February 2024 - In the pivotal Phase 3 COMMANDS study, Reblozyl nearly doubled the percentage of patients achieving primary endpoint of both transfusion independence and haemoglobin increase versus epoetin alfa.
Bristol Myers Squibb today announced the CHMP of the EMA has recommended approval of Reblozyl (luspatercept) as a treatment for adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes.
